What's Happening?
Veeva Systems is integrating industry-specific, agentic AI into medical, legal, and regulatory (MLR) processes to enhance content lifecycle management in the life sciences sector. This approach aims to create a faster, scalable, and more compliant workflow.
Moderna has recently implemented Veeva AI for PromoMats, which automates tasks to increase productivity and deliver compliant treatment information more efficiently. This integration represents a shift from AI as a theoretical concept to a practical tool, with expectations that 38% of the MLR process will be AI-driven by 2028.
Why It's Important?
The integration of AI into MLR processes is significant for the life sciences industry as it addresses bottlenecks in content management, allowing professionals to focus on high-risk content. This shift not only improves efficiency and compliance but also enhances the quality of information delivered to healthcare professionals and patients. As AI becomes more embedded in daily workflows, it could lead to substantial cost savings and improved operational efficiency for biopharmaceutical companies, ultimately benefiting the healthcare sector and patients.
What's Next?
As AI adoption in MLR processes continues, companies will need to focus on building trust and ensuring transparency in AI-driven workflows. The success of this integration will depend on the ability to balance technological advancements with human oversight. Companies like Moderna will likely continue to refine their AI strategies, setting benchmarks for others in the industry. Additionally, regulatory bodies may need to adapt their frameworks to accommodate the growing role of AI in life sciences.
